BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics
I'm PortAI, I can summarize articles.
BioNexus Gene Lab Corp. acquired a 15% stake in Fidelion Diagnostics via a non-cash share swap, with Fidelion holding 16.6% of BioNexus's stock. BioNexus secured exclusive rights to the VitaGuard™ MRD platform for Southeast Asia, supporting its expansion in precision oncology. The deal aims to preserve financial strength and minimize dilution.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments